

Neupogen, Granix Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🛭 Sam	e as Requesting Provider
Name:	
Fax:	Phone:
Rendering Provider Info: □ Sam Name:	ne as Referring Provider Same as Requesting Provider NPI#:
Fax:	Phone:
**	subject to dosing limits in accordance with FDA-approved labeling, ed compendia, and/or evidence-based practice guidelines.
Patient Weight:	kg
Patient Height:	cm
Please indicate the place of service	e for the requested drug:
	ome 🗖 Inpatient Hospital 🗖 Off Campus Outpatient Hospital
	spital 🗖 Office 🗇 Pharmacy

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Neupogen Granix CF STEP – 10/2018.

	What is the ICD-10 code?				
	The preferred product for you patient's plan is Zarxio. Can the patient's treatment be switched to Zarxio? ☐ Yes, <i>No Prior Authorization Required.</i> ☐ No				
	Did the patient have a documented previous treatment failure with Zarxio? <u>Action Required</u> : If 'Yes', attach supporting chart note(s). \square Yes, no further questions. \square No				
	Has the patient experienced a documented intolerable adverse event to Zarxio? <u>Action Required</u> : If 'Yes', attack supporting chart note(s). \square Yes, no further questions. \square No				
	Does the patient have a documented latex allergy and the prescriber has stated that the mem vials? <i>Action Required: If 'Yes', attach supporting chart note(s).</i> Yes, <i>no further questions</i>				
). <i>1</i>	Are Neupogen or Granix being requested for doses less than 180 mcg? ☐ Yes ☐ No				
	p Therapy Override: Complete if Applicable.		Circle		
	he requested drug being used to treat stage four advanced metastatic cancer? he requested drug's use consistent with the FDA-approved indication or the National	Yes	No		
Cor trea	mprehensive Cancer Network Drugs & Biologics Compendium indication for the atment of stage four advanced metastatic cancer and is supported by peer-reviewed	Yes	No		
medical literature? Is the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication OR an indication supported in the requested drug being used for an FDA-approved indication or an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug being used for an indication of the requested drug bei			No		
	he compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, cromedex, current accepted guidelines)?				
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?			No		
Do pha	patient chart notes document the requested drug was ordered with a paid claim at the irmacy, the pharmacy filled the prescription and delivered to the patient or other	Yes	No		
Has	sumentation that the requested drug was prescribed for the patient in the last 180 days? In the prescriber provided proof documented in the patient chart notes that in their opinion requested drug is effective for the patient's condition?	Yes	No		

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Neupogen Granix CF STEP – 10/2018.

CVS Caremark Specialty Pharmacy

Phone: 1-866-814-5506

Fax: 1-855-330-1720

www.caremark.com

Prescriber or Authorized Signature

Date (mm/dd/yy)